Ana Igea coauthor Cancer Cell breast cancer’s new therapy

Ana-Igea-rec Cancer Cell published yesterday this article:  Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells where Ana Igea is coauthor, in a work developed in the IRB, Barcelona. She is currently a postdoc researcher working at CINBIO, in the Immunology group. The importance of this work has been highlighted in national and international press, and rtve .

There are three major types of breast cancer, of which the triple negative is the one with the worst prognosis. While the other two can be treated through less aggressive specific therapies, the only known option so far for triple negative, which accounts for 15% of the cases, is chemotherapy.

The p38 protein, which “acts as a lifeline for tumor cells, preventing the excessive accumulation of mutations in their DNA that would lead to death,” and protein-inhibiting drugs were tested to block their function and cause mutations to accumulate in their DNA and, consequently, the death of these malignant cells. “These p38 inhibitors are now approved for use in patients affected by other diseases, so we know that their use is safe,” and their therapeutic use combined with taxanes, now the only therapy, and that will be improved. “Now we hope to get the pharmaceutical industry interested in conducting clinical trials to verify efficacy in patients.”

In the Singular Center of the University of Vigo, Igea is launching its own line of research, combining its knowledge in molecular biology and cancer with those of the CINBIO Immunology Group. The first project, led by Africa González, of this new line, aims at modulating the immune system in pancreatic cancer.

Other sources of information: